semaglutide april 22 2025 Did the FDA Ban Compounded and Tirzepatide? FDA Declares End to Semaglutide

This review article explores the mechanistic basis, pharmacological characteristics, and clinical data supporting the use of engineered NUSH-based peptide therapies for obesity and its related metabolic disorders, with particular emphasis on recent progress in the development and clinical application of dual and triple agonists

Oral delivery of anticoagulant doses of heparin: a randomized, double-blind, controlled study in humans

Zepbound and Other GLP-1 Options Zepbound , another option for weight management, follows a titration process similar to Mounjaro

Comparing peptide storage methods Understanding the relative merits of different storage approaches helps optimize peptide preservation